For instance, prostate specific membrane antigen (PSMA) based CART cells (chimeric antigen receptor T cells) and immune checkpoint inhibitors have been investigated in preclinical PCa models and show beneficial outcomes [206]. The gene discussed is FOLH1; the disease is posterior cortical atrophy.